4 Result(s)
within
Amanda M. Leisgang Osse
-
Article
Open AccessAlzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development
Alzheimer’s disease (AD) is a complex multifaceted disease. Recently approved anti-amyloid monoclonal antibodies slow disease progression by approximately 30%, and combination therapy appears necessary to prev...
-
Article
Open AccessAnti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease patients who have proven β-amyloid pathol...
-
Article
Open AccessClinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease
There is a tremendous need for identifying reliable blood-based biomarkers for Alzheimer’s disease (AD) that are tied to the biological ATN (amyloid, tau and neurodegeneration) framework as well as clinical as...
-
Article
Open AccessAlzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Novel agents addressing non-amyloid, non-tau targets in Alzheimer’s Disease (AD) comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most of the target processes identified...
